Stock listing

Shenzhen:300119 Tianjin Ringpu Bio-technology Co., Ltd. (瑞普生物) 股价

Follow Tianjin Ringpu Bio-technology Co., Ltd. into a list and get an email when it puts out news.

Share price · SZSE:300119

¥15.23 CNY -0.81 (-5.0%)

Close on Nov 20, 2026

Past year -23.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
¥15.13 – ¥15.67 CNYNov 20, 2026
Volume
4.03M sharesNov 20, 2026
Market cap
¥7.08B CNYAt the close on Nov 20, 2026 · price × 464.8M shares outstanding
52-week range
¥13.91 – ¥21.51 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
¥71.79M CNYMedian day 3.78M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Tianjin Ringpu Bio-technology Co., Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SZSE:300119 · CNY, adjusted for splits

DayCloseChange%OpenHighLowVolume
¥15.23-0.81-5.0%¥15.67¥15.67¥15.134,027,600
¥16.04-0.50-3.0%¥16.62¥16.70¥15.974,053,700
¥16.54-0.07-0.4%¥16.51¥16.82¥16.492,761,500
¥16.61+0.20+1.2%¥16.37¥16.68¥16.282,535,347
¥16.41-0.07-0.4%¥16.50¥16.79¥16.383,208,900
¥16.48-0.12-0.7%¥16.66¥16.77¥16.442,528,500
¥16.60-0.22-1.3%¥16.86¥16.88¥16.602,822,500
¥16.82-0.24-1.4%¥17.16¥17.16¥16.822,436,667
¥17.06-0.21-1.2%¥17.34¥17.37¥16.883,742,500
¥17.27+0.05+0.3%¥16.90¥17.55¥16.814,553,232
¥17.22+0.32+1.9%¥16.92¥17.22¥16.803,857,500
¥16.90-0.01-0.1%¥16.88¥17.10¥16.714,470,600
¥16.91+0.11+0.7%¥16.84¥17.05¥16.714,292,500
¥16.80+0.53+3.3%¥16.20¥16.96¥16.105,886,500
¥16.27+0.06+0.4%¥16.16¥16.65¥16.073,634,192
¥16.21-0.25-1.5%¥16.49¥16.63¥16.154,065,800
¥16.46+1.22+8.0%¥15.64¥16.59¥15.647,647,900
¥15.24-1.02-6.3%¥16.21¥16.43¥15.215,737,000
¥16.26+0.09+0.6%¥16.34¥16.48¥16.122,257,792
¥16.17+0.15+0.9%¥15.94¥16.24¥15.703,285,400
¥16.02-0.42-2.6%¥16.43¥16.55¥16.022,017,400
¥16.44+0.05+0.3%¥16.39¥16.69¥16.362,575,100
¥16.39+0.11+0.7%¥16.30¥16.68¥16.242,878,600
¥16.28+0.23+1.4%¥16.03¥16.37¥16.002,335,800
¥16.05-0.05-0.3%¥16.18¥16.52¥15.913,817,219
¥16.10-0.38-2.3%¥16.33¥16.46¥15.963,647,800
¥16.48+0.23+1.4%¥16.21¥16.63¥16.173,107,900
¥16.25-0.22-1.3%¥16.49¥16.49¥15.983,134,900
¥16.47-0.34-2.0%¥16.82¥16.97¥16.382,668,200
¥16.81+0.19+1.1%¥16.55¥16.89¥16.383,215,124
¥16.62-0.14-0.8%¥16.99¥17.28¥16.503,516,100
¥16.76+0.26+1.6%¥16.53¥16.90¥16.502,587,824
¥16.50-0.05-0.3%¥16.51¥16.78¥16.382,288,700
¥16.55-0.11-0.7%¥16.66¥16.81¥16.383,443,500
¥16.66-0.48-2.8%¥17.16¥17.33¥16.623,637,977
¥17.14-0.08-0.5%¥17.19¥17.29¥17.053,061,000
¥17.22+0.06+0.3%¥17.15¥17.34¥16.973,363,200
¥17.16+0.40+2.4%¥16.77¥17.30¥16.754,816,906
¥16.76-0.52-3.0%¥17.29¥17.42¥16.686,295,472
¥17.28+0.07+0.4%¥17.21¥17.38¥17.133,095,500
¥17.21-0.02-0.1%¥17.18¥17.71¥17.104,675,924
¥17.23-0.10-0.6%¥17.29¥17.69¥17.122,827,300
¥17.33+0.10+0.6%¥17.23¥17.38¥16.913,648,176
¥17.23-0.59-3.3%¥17.71¥17.77¥17.083,950,400
¥17.82-0.14-0.8%¥17.83¥18.02¥17.573,479,976
¥17.96-0.16-0.9%¥18.02¥18.18¥17.813,982,576
¥18.12-0.06-0.3%¥18.25¥18.33¥17.905,210,100
¥18.18+0.49+2.8%¥17.64¥18.31¥17.558,482,000
¥17.69+0.43+2.5%¥17.27¥17.98¥17.185,348,900
¥17.26-0.58-3.3%¥17.81¥18.05¥17.254,850,800
¥17.84+0.31+1.8%¥17.58¥18.02¥17.436,666,976
¥17.53+0.23+1.3%¥17.25¥17.86¥17.255,671,777
¥17.300.000.0%¥17.36¥17.56¥17.135,255,897
¥17.30+0.10+0.6%¥17.18¥17.37¥17.004,256,797
¥17.20+0.35+2.1%¥16.83¥17.22¥16.595,548,290
¥16.85-0.63-3.6%¥17.29¥17.60¥16.827,605,800
¥17.48+0.14+0.8%¥17.17¥17.62¥17.174,272,386
¥17.34-0.58-3.2%¥17.86¥18.13¥17.146,660,776
¥17.92-0.69-3.7%¥18.35¥18.42¥17.728,362,207
¥18.61+0.20+1.1%¥18.77¥19.59¥18.589,151,378

Splits

3 splits since 2011 · SZSE:300119 · every price before a split is adjusted for it

DayRatioWhat
1.9936-for-1Split
13-for-10Split
2-for-1Split
Ticker
Shenzhen:300119
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Shenzhen
Currency
CNY

Tianjin Ringpu Bio-technology Co., Ltd. on 6ix

Sector
Health care
Industry
Pharmaceuticals

Valuation

P/E 21.0× against a median of 22.4×: 4th lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
¥5.82B CNY
P/E
21.0×
EV/sales
1.6×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
1.5×
Gross margin
39.6%
Operating margin
13.0%
Net margin
9.6%
Debt to equity
0.1×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Tianjin Ringpu Bio-technology Co., Ltd. Class A · SZSE:300119US$1.06BUS$873.7M21.0×1.6×n/a1.5×9.6%0.1×n/a
Idorsia Ltd. · SIX:IDIAUS$1.15BUS$2.66Bn/a10.2×n/an/a−128.8%n/an/a
Harrow, Inc. · NASDAQ:HROWUS$1.14BUS$1.36Bn/a4.5×188×39.1×−9.4%10.0×1.31
Changzhou Qianhong Bio-Pharma Co., Ltd. Class A · SZSE:002550US$1.12BUS$929.9M32.3×4.1×n/a2.7×15.3%0.0×n/a
GC Biopharma Corp. · KRX:006280US$1.10BUS$1.30Bn/a0.9×13.2×1.2×−2.5%0.3×n/a
Vetoquinol SA · EURONEXT:VETOUS$1.09BUS$848.9M17.4×1.5×7.0×1.6×10.9%0.0×n/a
North China Pharmaceutical Company Ltd. Class A · SSE:600812US$1.09BUS$1.55B81.1×1.3×n/a1.3×1.1%0.8×n/a
Basilea Pharmaceutica AG · SIX:BSLNUS$1.07BUS$964.4M22.4×3.5×15.2×5.6×17.3%0.5×n/a
Beijing Foyou Pharma Co., Ltd. Class A · SSE:601089US$1.03BUS$710.8M18.7×1.3×n/a1.8×10.2%0.0×n/a
Chengdu Easton Biopharmaceuticals Co., Ltd. Class A · SSE:688513US$997.1MUS$737.6M24.4×3.8×n/a2.2×20.9%0.0×n/a
Jiangsu Kanion Pharmaceutical Co. Ltd. Class A · SSE:600557US$983.2MUS$677.1M20.8×1.3×n/a1.3×9.4%0.0×n/a
Median of the othersUS$1.09BUS$947.1M22.4×2.5×14.2×1.8×9.8%0.0×1.31

Forecasts

Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.

Price target
21.08 CNY · Analysts' mean
EPS, year to Dec 2026
0.84 · 1 analyst
Revenue, year to Dec 2026
3.69B · 5 analysts

Events

QuarterResultsShare move
Q3 2026Oct 29, 2026−1.1%
Q2 2026Aug 27, 2026+2.7%
Q1 2026Apr 28, 2026+1.9%
Q3 2025Oct 25, 2025+2.2%
Q2 2025Aug 26, 2025−4.3%
Q1 2025Apr 2, 2025 · Before open−0.8%
Q3 2024Oct 29, 2024 · Before open−3.1%
Q2 2024Aug 24, 2024−4.6%
Q1 2024Apr 25, 2024 · After close−2.5%
Q4 2023Mar 29, 2024 · Before open+4.0%
All 20 quarters
QuarterResultsShare move
Q3 2023Oct 25, 2023 · Before open−0.1%
Q2 2023Aug 25, 2023 · After close+5.6%
Q1 2023Apr 26, 2023 · After close−3.2%
Q4 2022Mar 31, 2023 · After close−0.2%
Q3 2022Oct 25, 2022 · After close+5.3%
Q2 2022Aug 25, 2022 · Before open+4.0%
Q1 2022Apr 28, 2022 · Before open−5.0%
Q4 2021Mar 25, 2022 · After close−2.5%
Quarter to Sep 30, 2021Oct 26, 2021 · After close−8.5%
Quarter to Jun 30, 2021Aug 26, 2021 · Before open−3.2%

Open Events

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue3.40B3.07B2.71B2.08B2.01B2.00B1.47B1.19B1.05B969.9M
Cost of revenue2.00B1.82B1.53B1.07B969.3M920.8M700.4M593.9M492.1M413.6M
Gross profit1.40B1.25B1.18B1.01B1.04B1.08B766.2M596.0M555.2M556.2M
Research and development253.0M206.6M172.9M132.7M117.7M111.5M94.8M80.3M85.3M76.6M
Selling, general and administrative351.1M188.9M174.0M142.8M150.3M165.1M141.4M110.1M103.0M174.4M
Operating income441.8M373.2M569.7M416.6M499.4M513.1M263.1M161.7M142.1M149.5M
Depreciation and amortization223.6M204.9M141.0M115.6M91.6M95.7M91.3M91.8M90.5M77.2M
EBITDA665.4M578.1M710.8M532.2M590.9M608.9M354.4M253.4M232.6M226.7M
Interest expense35.2M33.0M26.7M29.0M24.3M27.7M25.1M17.7M15.9M10.4M
Income before tax470.7M368.3M571.2M413.8M487.8M510.9M259.9M161.9M144.5M178.5M
Income tax38.5M56.2M40.0M54.2M71.4M36.1M20.9M19.7M25.2M
Net income400.5M300.7M453.6M346.7M412.8M398.2M194.4M119.0M104.9M132.8M
Earnings per share, basic0.860.650.980.751.031.010.490.290.260.34

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents651.2M487.4M335.4M384.4M1.31B294.5M396.4M287.9M397.8M295.0M
Short-term investments1.04B1.45B1.28B1.50B577.9M399.8M385.3M277.2M207.8M263.6M
Receivables983.6M1.14B1.02B742.5M606.6M466.6M373.1M399.8M351.1M312.7M
Inventory502.1M499.6M389.9M367.1M360.5M364.0M263.6M258.3M236.8M218.9M
Current assets3.37B3.65B3.26B3.09B3.06B1.60B1.53B1.36B1.32B1.17B
Property, plant and equipment1.30B1.11B1.03B953.9M929.3M935.6M
Goodwill443.0M442.3M67.8M67.8M67.8M67.8M67.8M67.8M67.8M70.1M
Total assets7.66B7.97B6.60B6.11B5.69B3.90B3.56B3.00B2.92B2.73B
Accounts payable436.8M550.2M562.0M148.5M65.4M22.2M201.6M203.6M175.6M173.1M
Current liabilities1.89B2.25B1.34B1.31B1.12B877.2M1.05B665.5M657.3M518.1M
Long-term debt368.4M513.8M307.1M191.2M90.1M98.1M55.3M9.23M15.4M
Total debt1.32B872.1M877.7M739.0M560.6M638.1M353.6M388.2M254.9M
Total liabilities2.47B2.96B1.79B1.61B1.37B1.16B1.21B744.0M748.0M627.7M
Shareholders' equity4.70B4.47B4.50B4.22B4.03B2.46B2.12B2.01B1.95B1.90B
Shares outstanding464.8M460.3M463.5M463.0M402.4M396.0M397.1M404.6M404.5M394.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations297.5M735.5M378.2M389.5M382.6M388.4M383.6M174.9M107.6M207.7M
Capital spending-176.1M-185.3M-244.5M-372.4M-305.9M-259.2M-229.7M-112.4M-108.9M-128.1M
Free cash flow121.4M550.2M133.7M17.1M76.8M129.3M153.9M62.4M-1.30M79.5M
Cash from investing-451.7M-161.0M-1.24B-627.1M-243.1M-397.8M-145.4M-58.3M-450.0M
Cash from financing-133.3M-272.5M-48.3M1.26B-169.9M92.6M-125.9M76.9M294.6M
Dividends paid-167.5M-215.8M-162.8M-163.7M-160.1M-100.1M-60.7M-80.3M-75.1M-70.0M
Share buybacks-115.1M-44.9M-1.79M-915.9K-100.5M
Change in cash149.3M151.3M-55.2M-903.5M1.02B-24.5M78.5M-96.5M126.2M52.3M

Open Financials

Cap table

Built by 6ix from Tianjin Ringpu Bio-technology Co., Ltd. Class A’s releases

Common shares
464,754,706
Fully diluted
464,754,706

Fully diluted

LineShares
Common shares464,754,706

Share count over time

CountShares
Nov 22, 2026464,754,706

Open Cap table

Shareholders

HolderSharesValueChangeAs of
Emerging Markets Core Equity 2 Portfolio255KUS$644K−65,500Jul 31, 2026
Dimensional Emerging Markets Value Fund134KUS$338K+94,400Jul 31, 2026
The Emerging Markets Small Cap Series81,135US$204KNo changeJul 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF60,500US$152KNo changeJul 31, 2026
Dimensional Emerging Core Equity Market ETF48,500US$122K+16,400Jul 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF30,100US$75,858+7,800Jul 31, 2026
Emerging Markets Social Core Equity Portfolio18,500US$46,620No changeJul 31, 2026
World ex U.S. Core Equity Portfolio17,400US$43,848No changeJul 31, 2026
Dimensional Emerging Markets Value ETF11,300US$28,478−9,100Jul 31, 2026
Emerging Markets Targeted Value Portfolio10,400US$26,208No changeJul 31, 2026
All 13 holders
HolderSharesValueChangeAs of
World ex U.S. Targeted Value Portfolio8,400US$21,168No changeJul 31, 2026
Emerging Markets Sustainability Core 1 Portfolio8,200US$20,664No changeJul 31, 2026
Dimensional Emerging Markets Sustainability Core 1 ETF1,100US$2,772No changeJul 31, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about Tianjin Ringpu Bio-technology Co., Ltd.